Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis

摘要: To evaluate the efficacy and safety of human lymphoblastoid interferon treatment (interferon alfa) for patients with compensated cirrhosis caused by hepatitis C virus (HCV) infection, we randomly assigned 82 cirrhotic chronic HCV infection (44 men, 38 women; mean age, 58.6 years) to two groups: 41 were treated alfa (480 million U over 6 months), other received no drug treatment. RNA genotypes determined polymerase chain reaction (PCR) testing using type-specific primers. levels measured competitive PCR testing. No untreated eliminated from serum or had a decrease in level alanine aminotransferase normal during observation period. Of 34 who completed treatment, (17.6%) considered complete responders end sustained this elimination throughout 6-month follow-up Complete constituted (46.2%) 13 10(5) copies/50 microL responders. Two (7.1%) 28 genotype 1b 4 (66.7%) 2a Five withdrew because alfa-induced side effects (1 thrombocytopenia, 3 severe general malaise, 1 impotence), 2 after being diagnosed hepatocellular carcinoma. Hepatic failure did not occur any patient present study. These findings indicate that is useful if are low 2a.